ZUG, Switzerland, and BOSTON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, ...
If approved, OCS-01 has the potential to become the first topical eye drop and non-invasive treatment option for DME ZUG, Switzerland, and BOSTON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG ...
DIAMOND-1 Phase 3 trial, assessing the efficacy and safety of OCS-01 eye drops following 52 weeks of treatment in Diabetic Macular Edema (DME) patients, was initiated as planned Stage 1 results showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results